Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. (“Filana Therapeutics”, or the “Company”). The new name and corporate brand reflect the Compa ...